These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15280844)

  • 41. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
    McGinnis KS; Junkins-Hopkins JM; Crawford G; Shapiro M; Rook AH; Vittorio CC
    J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
    Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
    J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents.
    Kimball AB; Gold MH; Zib B; Davis MW;
    J Am Acad Dermatol; 2008 Sep; 59(3):448-54, 454.e1. PubMed ID: 18539358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
    Kalb RE; Gurske J
    J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial.
    Berger R; Rizer R; Barba A; Wilson D; Stewart D; Grossman R; Nighland M; Weiss J
    Clin Ther; 2007 Jun; 29(6):1086-97. PubMed ID: 17692723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
    Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
    Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer.
    Luo W; Schork NJ; Marschke KB; Ng SC; Hermann TW; Zhang J; Sanders JM; Tooker P; Malo N; Zapala MA; Dziewanowska ZE; Negro-Vilar A; Meglasson MD
    Anticancer Res; 2011 Jun; 31(6):2303-11. PubMed ID: 21737656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
    Heald P; Mehlmauer M; Martin AG; Crowley CA; Yocum RC; Reich SD;
    J Am Acad Dermatol; 2003 Nov; 49(5):801-15. PubMed ID: 14576658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
    Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
    J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
    Cabello I; Servitje O; Corbella X; Bardés I; Pintó X
    Clin Exp Dermatol; 2017 Apr; 42(3):276-281. PubMed ID: 28233333
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bexarotene: a clinical review.
    Farol LT; Hymes KB
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):180-8. PubMed ID: 15056048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bexarotene.
    Lowe MN; Plosker GL
    Am J Clin Dermatol; 2000; 1(4):245-50; discussion 251-2. PubMed ID: 11702369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of body mass index on the severity of bexarotene-associated hypertriglyceridemia: A post hoc analysis of an open-labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T-cell lymphoma.
    Sanagawa A; Hayakawa T; Nishida E; Yamamoto A; Ikumi K; Mori Y; Hotta Y; Kimura K; Furukawa-Hibi Y; Morita A
    J Dermatol; 2023 Jul; 50(7):917-926. PubMed ID: 37041679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bexarotene (Targretin) for cutaneous T-cell lymphoma.
    Med Lett Drugs Ther; 2000 Apr; 42(1075):31-2. PubMed ID: 10788961
    [No Abstract]   [Full Text] [Related]  

  • 59. Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature.
    Sanli H; Akay BN; Ozcan M
    J Drugs Dermatol; 2010 Aug; 9(8):1014-6. PubMed ID: 20684154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials.
    Prince HM; McCormack C; Ryan G; Baker C; Rotstein H; Davison J; Yocum R
    Australas J Dermatol; 2001 May; 42(2):91-7. PubMed ID: 11309029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.